Recent advances in immunostimulatory CpG oligonucleotides.
S Rothenfusser, E Tuma, M Wagner… - Current Opinion in …, 2003 - europepmc.org
The vertebrate immune system has evolved a mechanism to detect CpG motifs within
microbial DNA (CpG DNA). Synthetic oligonucleotides containing CpG motifs (CpG ODNs) …
microbial DNA (CpG DNA). Synthetic oligonucleotides containing CpG motifs (CpG ODNs) …
Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates
D Verthelyi, DM Klinman - Clinical Immunology, 2003 - Elsevier
Oligodeoxynucleotides (ODN) containing CpG motifs mimic the ability of microbial DNA to
activate the innate immune system. The resultant response limits the early spread of …
activate the innate immune system. The resultant response limits the early spread of …
CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials
CpG oligodeoxynucleotides (CpG ODNs), the artificial versions of unmethylated CpG motifs
that were originally discovered in bacterial DNA, are demonstrated not only as potent …
that were originally discovered in bacterial DNA, are demonstrated not only as potent …
Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine
Y Kojima, KQ Xin, T Ooki, K Hamajima, T Oikawa… - Vaccine, 2002 - Elsevier
Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs trigger an
immune response characterized by the activation of B cells, NK cells and monocytes …
immune response characterized by the activation of B cells, NK cells and monocytes …
Synthetic oligonucleotides as modulators of inflammation
D Klinman, H Shirota, D Tross, T Sato… - Journal of Leucocyte …, 2008 - academic.oup.com
Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs mimic the
immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate human B cells and …
immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate human B cells and …
CpG DNA is an effective oral adjuvant to protein antigens in mice
MJ McCluskie, RD Weeratna, AM Krieg, HL Davis - Vaccine, 2000 - Elsevier
We have previously reported that synthetic oligodeoxynucleotides containing
immunostimulatory CpG motifs (CpG ODN) are potent adjuvants to protein administered by …
immunostimulatory CpG motifs (CpG ODN) are potent adjuvants to protein administered by …
CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques
DM Klinman, H Xie, SF Little, D Currie, BE Ivins - Vaccine, 2004 - Elsevier
Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune
adjuvants, improving the immune response elicited by co-administered vaccines. Combining …
adjuvants, improving the immune response elicited by co-administered vaccines. Combining …
From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA
AM Krieg - Antisense and Nucleic Acid Drug Development, 2001 - liebertpub.com
Several types of immune cells possess pattern recognition receptors (PRR) that can
distinguish prokaryotic DNA from vertebrate DNA by detecting unmethylated CpG …
distinguish prokaryotic DNA from vertebrate DNA by detecting unmethylated CpG …
An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems
PP Ho, P Fontoura, PJ Ruiz, L Steinman… - The Journal of …, 2003 - journals.aai.org
Bacterial DNA and immunostimulatory CpG oligodeoxynucleotides (ODNs) activate the
innate immune system to produce proinflammatory cytokines. Shown to be potent Th1-like …
innate immune system to produce proinflammatory cytokines. Shown to be potent Th1-like …
CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
B Jahrsdörfer, GJ Weiner - Current opinion in investigational drugs …, 2003 - europepmc.org
Synthetic oligodeoxynucleotides containing CG motifs (CpG ODNs) have potent
immunostimulatory properties, and have potential as immunotherapeutic agents in cancer …
immunostimulatory properties, and have potential as immunotherapeutic agents in cancer …